These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 15980902

  • 1. Benzbromarone therapy in management of refractory gout.
    Kumar S, Ng J, Gow P.
    N Z Med J; 2005 Jun 24; 118(1217):U1528. PubMed ID: 15980902
    [Abstract] [Full Text] [Related]

  • 2. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A.
    Arthritis Rheum; 2002 Aug 24; 47(4):356-60. PubMed ID: 12209479
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR.
    Ann Rheum Dis; 2009 Jan 24; 68(1):51-6. PubMed ID: 18250112
    [Abstract] [Full Text] [Related]

  • 4. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Mertz DP.
    Med Klin; 1977 Apr 15; 72(15):664-8. PubMed ID: 857138
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Hanvivadhanakul P, Akkasilpa S, Deesomchok U.
    J Med Assoc Thai; 2002 Jun 15; 85 Suppl 1():S40-7. PubMed ID: 12188443
    [Abstract] [Full Text] [Related]

  • 6. [The effect of benzbromaron in gout patients with limited kidney function].
    Kuzmits R, Bresnik W, Müller MM.
    Fortschr Med; 1979 Nov 22; 97(44):2057-61. PubMed ID: 511087
    [Abstract] [Full Text] [Related]

  • 7. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
    Matzkies F.
    Med Klin (Munich); 1992 Sep 15; 87(9):460-2. PubMed ID: 1406482
    [Abstract] [Full Text] [Related]

  • 8. Gout--what are the treatment options?
    Schlesinger N, Dalbeth N, Perez-Ruiz F.
    Expert Opin Pharmacother; 2009 Jun 15; 10(8):1319-28. PubMed ID: 19463070
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S, Osiri M, Deesomchok U, Avihingsanon Y.
    J Med Assoc Thai; 2004 Sep 15; 87(9):1087-91. PubMed ID: 15516011
    [Abstract] [Full Text] [Related]

  • 10. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR.
    Ann Rheum Dis; 2009 Jun 15; 68(6):892-7. PubMed ID: 18633127
    [Abstract] [Full Text] [Related]

  • 11. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK, Haslett J, Frampton C, White D, Gardner D, Stebbings S, Taylor G, Grainger R, Kumar R, Kumar S, Kain T, Porter D, Corkill M, Cathro A, Metcalfe S, Wyeth J, Dalbeth N.
    Intern Med J; 2016 Sep 15; 46(9):1075-80. PubMed ID: 27391386
    [Abstract] [Full Text] [Related]

  • 12. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
    Mertz DP.
    Dtsch Med Wochenschr; 1976 Aug 27; 101(35):1288-92. PubMed ID: 782809
    [No Abstract] [Full Text] [Related]

  • 13. [Effect of benziodarone and benzbromarone on the uric acid level in the blood and urine and on the incidence of gout attacks].
    Brzozowska-Jurkowska AM.
    Reumatologia; 1980 Aug 27; 18(3):287-92. PubMed ID: 6999575
    [No Abstract] [Full Text] [Related]

  • 14. [Clinical studies on hyperuricemia and gout after transplantation].
    Imanishi M, Ikegami M, Ishii T, Nishioka T, Uemura T, Kunikata S, Kanda H, Matsuura T, Akiyama T, Kurita T.
    Hinyokika Kiyo; 1990 Aug 27; 36(8):893-6. PubMed ID: 2239590
    [Abstract] [Full Text] [Related]

  • 15. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
    Matzkies F, Neuwirth R, Berg G.
    Fortschr Med; 1976 Sep 16; 94(26):1427-9. PubMed ID: 976920
    [Abstract] [Full Text] [Related]

  • 16. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.
    Arthritis Rheum; 2008 Nov 15; 59(11):1540-8. PubMed ID: 18975369
    [Abstract] [Full Text] [Related]

  • 17. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, Yancopoulos GD, Wang J, Terkeltaub R.
    Arthritis Care Res (Hoboken); 2012 Oct 15; 64(10):1462-70. PubMed ID: 22549879
    [Abstract] [Full Text] [Related]

  • 18. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L, Wei L, Chen H, Zhang Z, Yu Q, Ji Z, Jiang L.
    Clin Rheumatol; 2016 Jan 15; 35(1):133-41. PubMed ID: 25373449
    [Abstract] [Full Text] [Related]

  • 19. Ten years' experience with benzbromarone in the management of gout and hyperuricaemia.
    Masbernard A, Giudicelli CP.
    S Afr Med J; 1981 May 09; 59(20):701-6. PubMed ID: 7221794
    [Abstract] [Full Text] [Related]

  • 20. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N, Kumar S, Stamp L, Gow P.
    J Rheumatol; 2006 Aug 09; 33(8):1646-50. PubMed ID: 16783857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.